for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Roche Holding Ltd.

ROG.S

Latest Trade

297.85CHF

Change

-0.05(-0.02%)

Volume

122,107

Today's Range

297.20

 - 

298.95

52 Week Range

233.60

 - 

298.95

As of on the Virt-X ∙ Minimum 15 minute delay

Pricing

Previous Close
297.90
Open
297.50
Volume
122,107
3M AVG Volume
37.63
Today's High
298.95
Today's Low
297.20
52 Week High
298.95
52 Week Low
233.60
Shares Out (MIL)
856.06
Market Cap (MIL)
255,925.10
Forward P/E
15.23
Dividend (Yield %)
2.79

Next Event

Roche Holding AG at Jefferies London Healthcare Conference

Latest Developments

More

Roche Presents Results Of Phase II Gazyva Study

Dicerna & Roche To Develop DCR-HBVS For Treatment Of Chronic Hepatitis B Virus Infection

Roche: FDA Accepts Genentech's Biologics License Application For Satralizumab

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Roche Holding Ltd.

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Industry

Major Drugs

Contact Info

Grenzacherstr. 124

+41.9.732354295

http://www.roche.com

Executive Leadership

Severin Schwan

Chairman of the Corporate Executive Committee, Chief Executive Officer, Executive Director

Christoph Franz

Non-Executive Independent Chairman of the Board

Fritz Gerber

Honorary Chairman of the Board

Andre S. Hoffmann

Non-Executive Independent Vice Chairman of the Board

Alan Hippe

Member of the Corporate Executive Committee, Chief Financial Officer, Information Technology Officer

Key Stats

2.24 mean rating - 25 analysts
Sell
Hold
Buy
Revenue (MM, CHF)

2016

50.6K

2017

53.3K

2018

56.8K

2019(E)

62.1K
EPS (CHF)

2016

14.530

2017

15.340

2018

18.140

2019(E)

19.760
Price To Earnings (TTM)
21.82
Price To Sales (TTM)
4.32
Price To Book (MRQ)
9.09
Price To Cash Flow (TTM)
15.88
Total Debt To Equity (MRQ)
69.75
LT Debt To Equity (MRQ)
54.88
Return on Investment (TTM)
23.03
Return on Equity (TTM)
15.43

Latest News

Latest News

BRIEF-Roche Presents Results Of Phase II Gazyva Study

* ANNOUNCES DATA FROM PHASE II NOBILITY STUDY, INVESTIGATING THE SAFETY AND EFFICACY OF GAZYVA

BRIEF-Roche: FDA Accepts Genentech's Biologics License Application For Satralizumab

* FDA ACCEPTS GENENTECH'S BIOLOGICS LICENSE APPLICATION FOR SATRALIZUMAB FOR NEUROMYELITIS OPTICA SPECTRUM DISORDE Source text for Eikon: Further company coverage: (Reporting by Berlin Speed Desk)

BRIEF-UK competition watchdog launches Roche-Spark inquiry

* UK'S CMA - CONSIDERING WHETHER ROCHE-SPARK DEAL MAY RESULT IN LESSENING OF COMPETITION WITHIN ANY MARKET OR MARKETS IN UK FOR GOODS OR SERVICES

BRIEF-Roche Holding: FDA Approval For Xofluza

* ROCHE ANNOUNCES FDA APPROVAL OF XOFLUZA (BALOXAVIR MARBOXIL) FOR PEOPLE AT HIGH RISK OF DEVELOPING INFLUENZA-RELATED COMPLICATIONS

AstraZeneca breast cancer treatment gets FDA priority review

AstraZeneca Plc said on Thursday that the U.S. drug regulator will give a speedy review to its experimental breast cancer treatment, which could put the British drugmaker in direct competition with bigger rival Roche Holding AG.

BRIEF-Roche CEO does not expect U.S. to slap tariffs on European drugs

* CEO SAYS BELIEVES CONCERNS, REPORTS ABOUT U.S. TARIFFS IMPACT ON SWISS DRUGMAKERS 'BASED ON WRONG FACTS'

BRIEF-Roche Says Phase 3 Study Shows Mabthera/Rituxan Superior To Mycophenolate Mofetil In Patients With Pemphigus Vulgaris

* PHASE III PEMPHIX STUDY SHOWS ROCHE’S MABTHERA/RITUXAN (RITUXIMAB) SUPERIOR TO MYCOPHENOLATE MOFETIL IN PATIENTS WITH PEMPHIGUS VULGARIS

BRIEF-Roche: Tecentriq Reduced Risk Of Disease Worsening Compared With Chemotherapy Alone

* IMVIGOR130 IS THE FIRST POSITIVE PHASE III STUDY OF A CANCER IMMUNOTHERAPY COMBINATION IN PEOPLE WITH PREVIOUSLY UNTREATED ADVANCED BLADDER CANCER

BRIEF-Roche To Announce Positive Results From Study Using Blood-Based NGS To Detect Specific Fusions

* WILL TODAY ANNOUNCE POSITIVE RESULTS FROM A SINGLE-ARM COHORT OF THE PHASE II/III BLOOD FIRST ASSAY SCREENING TRIAL (BFAST), THE FIRST PROSPECTIVE STUDY TO USE ONLY BLOOD-BASED NEXT GENERATION SEQUENCING (NGS) TO DETECT SPECIFIC FUSIONS Source text for Eikon: Further company...

BRIEF-Roche says Tecentriq-Avastin cocktail shows promise in liver cancer

* SAYS TECENTRIQ IN COMBINATION WITH AVASTIN SHOWS ENCOURAGING RESULTS IN PHASE IB STUDY OF PEOPLE WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA

BRIEF-Roche Company Chugai Says Obtained Approval For Additional Indication And Formulation For Tecentriq In Pd-L1-Positive Triple Negative Breast Cancer In Japan

* COMPANY CHUGAI SAYS OBTAINED APPROVAL FOR ADDITIONAL INDICATION AND FORMULATION FOR TECENTRIQ IN PD-L1-POSITIVE TRIPLE NEGATIVE BREAST CANCER IN JAPAN Source text for Eikon: Further company coverage:

BRIEF-Roche Receives FDA Clearance For Cobas Pro Integrated Solutions

* ROCHE RECEIVES FDA CLEARANCE FOR COBAS PRO INTEGRATED SOLUTIONS DESIGNED TO HELP LABS DELIVER FASTER RESULTS TO PATIENTS

BRIEF-Roche: Update On Genentech’s Breast Cancer Therapy

* GENENTECH’S FIXED DOSE SUBCUTANEOUS COMBINATION OF PERJETA AND HERCEPTIN SHOWED NON-INFERIORITY WHEN COMPARED TO INTRAVENOUS FORMULATIONS FOR PEOPLE WITH HER2-POSITIVE BREAST CANCER

BRIEF-Roche Reports Positive Data From Phase III Impower110 Study Evaluating Tecentriq

* ROCHE’S TECENTRIQ AS A FIRST-LINE MONOTHERAPY HELPED CERTAIN PEOPLE WITH ADVANCED NON-SMALL CELL LUNG CANCER LIVE LONGER COMPARED WITH CHEMOTHERAPY

BRIEF-Europe OKs Roche’S Tecentriq cocktail for non-small cell lung cancer

* EUROPEAN COMMISSION APPROVES ROCHE'S NEW TECENTRIQ-BASED COMBINATION THERAPY AS AN INITIAL TREATMENT FOR MOST COMMON FORM OF ADVANCED LUNG CANCER

Roche, Spark again extend $4.3 billion takeover offer

Roche Holding <ROG.S> and Spark Therapeutics <ONCE.O> announced on Tuesday another extension of the Swiss drugmaker's $4.3 billion takeover offer for the U.S. gene therapy specialist as regulatory reviews continue.

BRIEF-Roche Presents Positive Study Results For One-Dose Xofluza In Children With Flu

* ROCHE PRESENTS POSITIVE PHASE III STUDY RESULTS FOR ONE-DOSE XOFLUZA IN CHILDREN WITH FLU

BRIEF-Enable Injections Enters Into Partnership With Genentech

* ENABLE INJECTIONS ENTERS INTO STRATEGIC PARTNERSHIP WITH GENENTECH, A MEMBER OF THE ROCHE GROUP

Roche taps Lilly executive Garraway as chief medical officer

Swiss drugmaker Roche Holding on Monday named Eli Lilly executive Levi Garraway to succeed Sandra Horning as chief medical officer and head of global product development.

Roche taps Eli Lilly executive as chief medical officer

Swiss drugmaker Roche Holding on Monday named Eli Lilly executive Levi Garraway to succeed Sandra Horning as chief medical officer and head of global product development.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up